Latest Research
All publications from the Cancer3.AI database, newest first.
Failure of the Galleri multi-cancer detection trial to meet its primary endpoint.
Diamandis EP
A commentary published in the journal Diagnosis examines interim results from a large, ongoing randomized clinical trial in the United Kingdom evaluating the Galleri multi-cancer early detection test, developed by Grail Inc. The Galleri test uses circulating tumor DNA (ctDNA), fragments of genetic material shed by tumors into the bloodstream, to simultaneously screen for 40 to 50 different cancer types from a single blood draw. Current evidence-based guidelines, such as those from the U.S. Preventive Services Task Force, recommend routine cancer screening for only a limited number of cancers, making broad multi-cancer detection tests a highly anticipated potential advance in oncology. Analysis of the trial's newest data revealed that the Galleri test failed to meet its primary clinical endpoint, which required at least a 20% reduction in the incidence of late-stage (stage III–IV) cancers among screened participants. Although the trial remains ongoing and definitive conclusions cannot yet be drawn, these findings raise important questions about the real-world clinical effectiveness of ctDNA-based multi-cancer screening and urge caution before such tests are widely adopted into routine medical practice.
Diagnosis (Berlin, Germany)
Source →SRY-box transcription factor 7 functions as a tumor suppressor regulating Wnt signaling and cancer stemness with its promoter methylation as a potential biomarker.
Xie L, et al
Researchers investigated the role of SOX7, a transcription factor, in gastric cancer, focusing on whether silencing of this gene through a chemical modification called DNA methylation drives tumor development. The study found that SOX7 is normally active in healthy stomach tissue but is frequently switched off in gastric cancer cells when its promoter region becomes methylated, and patients whose tumors showed this methylation had significantly worse survival outcomes. When SOX7 expression was experimentally restored in gastric cancer cells, it suppressed tumor growth by triggering cell cycle arrest, programmed cell death (apoptosis), and ferroptosis — an iron-dependent form of cell death — while also reducing the cells' ability to migrate and invade surrounding tissue. Mechanistically, SOX7 was shown to block the Wnt/beta-catenin signaling pathway — a major driver of tumor growth and cancer stem cell properties — by trapping active beta-catenin in the cytoplasm and directly binding to the promoters of Wnt target genes such as c-MYC, thereby shutting down their cancer-promoting activity. These findings firmly establish SOX7 as a tumor suppressor in gastric cancer and suggest that measuring SOX7 promoter methylation in patient samples could serve as a clinically useful biomarker for early detection of gastric cancer and for predicting patient prognosis.
Cellular signalling
Source →Giant plexiform fibromyxoma of the esophagus.
Swatek P, et al
Surgeons report only the third known case of plexiform fibromyxoma — an exceptionally rare, benign gastrointestinal tumor — originating from the esophagus, and the first case involving a giant, rapidly growing mass requiring major surgery. A 73-year-old patient presented with dysphagia, chest pain, fever, and weight loss caused by an 11 × 7 × 7 cm tumor compressing the esophagus, trachea, and heart simultaneously. FDG-PET imaging strongly suggested malignancy, and an intraoperative frozen-section biopsy initially indicated esophageal sarcoma, illustrating the profound diagnostic challenge this tumor can pose. The patient underwent transthoracic esophagectomy with gastric pull-up reconstruction and was successfully discharged on the twelfth postoperative day without complications. Final histopathological analysis ultimately confirmed the benign diagnosis of plexiform fibromyxoma, underscoring that this tumor can mimic aggressive malignancies and that definitive tissue examination is essential before reaching clinical conclusions.
Wiener klinische Wochenschrift
Source →Utility of Pelvic Peritoneum Closure After Minimally Invasive Low Anterior Resections for Rectal Cancer. A Systematic Review and Meta-Analysis.
Patriti A, et al
A systematic review and meta-analysis published in the Journal of Laparoendoscopic & Advanced Surgical Techniques examined whether surgically closing the pelvic peritoneum — the tissue lining the pelvic cavity — during minimally invasive low anterior resection for rectal cancer can reduce serious postoperative complications. Researchers pooled data from seven observational studies involving 2,753 patients and compared outcomes between those who received pelvic peritoneum closure and those who did not. The analysis found that closure was associated with a roughly three-fold reduction in severe postoperative complications requiring further intervention, with an odds ratio of 0.34 and no statistical heterogeneity between studies, while anastomotic leakage — a dangerous breakdown of the surgical join in the bowel — was also reduced. The technique added approximately 11 minutes to operative time, but hospital stay duration and perioperative mortality were similar between the two groups, and limited data suggested better bowel function after closure. Because all included studies were observational rather than randomized, the authors urge caution in interpreting these promising results and call for well-powered randomized controlled trials before pelvic peritoneum closure can be recommended as standard surgical practice.
Journal of laparoendoscopic & advanced surgical techniques. Part A
Source →Discontinuous Involvement of the Spermatic Cord by Germ Cell Tumors Should Not Be Considered Pathologic Stage M1: An International Multi-Institutional Study.
Lobo J, et al
A new international multi-institutional study challenges current guidelines for staging testicular germ cell tumors (TGCTs), specifically the practice of classifying discontinuous spermatic cord involvement as pathologic stage M1 (distant metastasis) under the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual. Researchers evaluated 19 patients — 16 with nonseminomatous tumors and 3 with seminomas — who had isolated tumor deposits in the spermatic cord that were discontinuous from the primary tumor but showed no other evidence of metastasis. A critical observation was that all 4 patients managed with active surveillance rather than chemotherapy remained recurrence-free at last follow-up, a finding that is incompatible with the natural history of genuine stage III metastatic disease. In contrast, 10 of 15 patients who received adjuvant chemotherapy experienced disease recurrence, suggesting that aggressive treatment did not reliably prevent relapse in this group and that current staging may not accurately reflect disease biology. The authors propose a new staging designation, pT3(disc), to classify discontinuous cord involvement as a local risk factor for recurrence rather than evidence of distant spread, thereby avoiding inappropriate upstaging from clinical stage I to III. Adopting this reclassification could spare patients from unnecessary chemotherapy toxicity and allow eligible individuals to remain safely on active surveillance.
The American journal of surgical pathology
Source →